Mosaic Biosciences’ Post

Here is the official flyer of the third virtual winter school INTERACTION WINS next month. https://lnkd.in/eq9Pyr69 You can register online. INTERACTION WINS 2024 aims at familiarize the young scientists with general methodologies for investigating nucleic acid structures, support international collaborations, and provide a platform for free discussions on the limitations and prospects of nucleic acids-targeting therapeutics!

Review our latest preclinical development data as presented at CICON23: 'STRIKE2001-KRAS, a novel CD40-targeting agonistic antibody carrying KRAS peptide cargo via a modular drug cargo loading principle (ADACTM) leading to simultaneous agonism and antigen-presentation in vivo.' As always, our Chief Scientific Officer, Associate Professor Sara Mangsbo, will be happy to hear from you if you would like further information. #biotechnology #cancerimmunotherapy #immunooncology #therapeuticvaccines

Missed the webinar? No problem! 🎥 Watch the playback of "Accelerating Antibody Drug Discovery with Fully Human Antibody Mouse HUGO-Ab™ and High-Throughput Single B Cell Screening AbDrop™". 🔗 https://lnkd.in/gBtAEYWS 💡 Ready to elevate your antibody drug discovery journey? Share your thoughts and explore further insights in the comments below! #Webinar #AntibodyDrugDiscovery #HUGOAb #AbDrop #Biotech #Research #Cyagen #antibody #scienceandcommunication

Since its first application in 1983, the 3-(4,5-dimethyl- thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay, also known as the MTT assay, has become the method of choice for determining cell viability and proliferation. Scientists use MTT assays in drug discovery to screen primary therapeutics and evaluate their antigrowth and toxicity effects on cells. During the assay, the yellow-colored, positively charged MTT reagent crosses the cell membrane, where the cell then metabolizes the chemical into formazan crystals, triggering a visible color change to purple. The darker the purple, the more viable cells within the solution. When automating reagent dispensing for an MTT assay, researchers should consider the following instrument needs: To find out more, click here: https://lnkd.in/ejkgpQNJ #Acceleratescientificdiscovery #MakePipettingMoreProductive #IntegraBiosciences

Excited to share my latest IT research plunge into the Nucleocapsid Protein of SARS-CoV-2! Exploring the intricate coding and potential implications for diagnostics and therapeutics. #COVID19  #research #bioinformatics

Accelerate your antibody discovery process with the AbNano™ VHH Naïve Library from Abcore | Fortis Life Sciences 🦙 The AbNano™ VHH Naïve Library is a fully natural, single domain naïve library derived from camelid source material and the antibodies displayed on monovalent phage. It is intended for research purposes to aid in the discovery of antibodies intended for use as therapeutics, diagnostics, and research tools. Learn more at https://ow.ly/VYhG50QQI7K #DrugDiscovery #DrugDevelopment #AntibodyDiscovery #AntibodyEngineering #TherapeuticAntibodies #BiotechInnovation #PhageDisplay

This is an awesome option for folks who want to find single-domain Abs / VHH binders quickly! It's a ready-to-screen phage library displaying sdAbs from the immune repertoire of naïve/un-immunized llamas (and some alpacas). Order it and identify the best binders yourself, or have the Abcore | Fortis Life Sciences folks screen it against your target. Should be way faster than the standard immunization-based discovery workflow.

"We have more possibilities available in each moment than we realize." -Thich Nhat Hanh The possibilities for therapeutics are expanding with the help of bispecific, multispecific, and other antibody derivatives. 🧪 Learn more about the technology and how transient protein expression pilots can accelerate lead identification: https://lnkd.in/ehyBg8vk #ilovemolbio #antibodyderivatives #transientproteinexpression

👇 #Bococizumab Video Case Study - how to identify & remedy potential late-stage problematic antibodies in advance! Short case study delivered by Chief Technology Officer, Peter S. at Antibody Engineering & Therapeutics (credit) 📝 Key takeaways: ✅ Mammalian display is highly predictive of late stage (CMC) developability properties ✅ Can be applied to many millions of clones in any desired final format ✅ Can simultaneously engineer biophysical and binding properties ✅ Saving you significant time and money in development Contact us to discover how FairJourney Biologics proprietary Mammalian Display technology can empower your antibodies journey to clinic for better patient outcomes: https://lnkd.in/dzDY7xuC For further reading, visit supporting paper published in mAbs: https://lnkd.in/dvy2nCvs - National Library of Medicine (NLM) #antibody #discovery #technology #biotechnology #antibodies

On February 20, 2024, researchers published the latest results in Cell Reports Medicine on the marine natural small molecule Benzoceptrin C that exerts immune and anti-tumor effects by targeting DHHC3 to degrade PD-L1, providing a new approach for target discovery and mechanism research on small molecule drugs regulating PD-L1. Due to the small molecular weight, PD-L1 small molecule inhibitors have negligible immunogenicity. Targeted regulation of PD-L1 expression small molecules may become a new way of treatment, so finding natural small molecules that regulate PD-L1 expression will become a new solution in the immunotherapy process. 🔗https://lnkd.in/gQrSsudx #APTBIO #LipMS #proteomics